UKOF 2023 Symposium

Professor Richard Wilson chairs this symposium joined by speakers Dr Janet Graham, Professor Richard Adams and Professor Mark Saunders, as they share their experience and discuss the latest clinical data in mCRC, treatment sequencing and where Stivarga® (regorafenib) fits into the treatment pathway.

Watch the trailer to learn more!

Stivarga Prescribing Information

Dr Janet Graham shares the latest clinical trial data that may shape the evolving treatment landscape in mCRC

Stivarga Prescribing Information

Professor Richard Adams discusses the antitumour activity of Stivarga, when to use it, what the key clinical trial and real-world data are, as well as his experience of managing common side effects

Stivarga Prescribing Information

Professor Mark Saunders shares best practice for mCRC treatment sequencing based on his experience and where Stivarga and other treatment options fit in to optimise patient outcomes

Stivarga Prescribing Information

Professor Richard Wilson, Dr Janet Graham, Professor Richard Adams and Professor Mark Saunders answer five key questions on using Stivarga in clinical practice, including potential biomarkers, managing side effects and the importance of patient-reported outcomes in trials

Stivarga Prescribing Information

Professor Richard Wilson completed his medical degree at the Queen’s University Belfast (QUB) and worked as a junior doctor in Northern Ireland and Scotland. He undertook basic science research in colorectal cancer for which he received his doctoral degree. He subsequently trained in clinical oncology in N. Ireland and attained UK accreditation. Following this, he undertook a Fellowship at the National Cancer Institute in the US National Institutes of Health where he received specialist training in medical oncology, early-phase cancer clinical trials and drug development. He returned to the UK as a clinical academic in QUB and the Belfast Health and Social Care Trust. He set up the early phase cancer clinical trials programme in Belfast and the N. Ireland Cancer Trials Network. He moved in February 2019 from his position as Professor in Cancer Medicine in QUB to the University of Glasgow where he is Professor of Gastrointestinal Oncology and also Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre. He works in lower gastrointestinal cancer (mainly in colorectal cancer but also in small bowel cancer and peritoneal malignancies) and conducts biological, translational and clinical research in these diseases. He is Chief Investigator on many local, national and international cancer clinical trials in both early and late-phase settings. He previously chaired the UK National Cancer Research Institute Colorectal Cancer Clinical Studies Group and is a member of its Adjuvant and Advanced Disease Subgroup.

Dr Janet Graham completed a PhD at Imperial College London before taking up a post as Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, based in Glasgow. She is the Gastrointestinal team lead and Clinical Lead for the West of Scotland Colorectal Cancer Managed Clinical Network. As a Senior NRS Research Fellow her main focus is on trying to maximise opportunities for OG, pancreatic and colorectal patients to take part in clinical trials. Nationally Janet was Chair of the Adjuvant and Advanced Subgroup of the NCRI Colorectal Group until recently and also advises other groups such as bowel cancer UK, NICE and SMC.

Professor Richard Adams is a Clinical Senior Lecturer of Oncology & Palliative Medicine, Cardiff University School of Medicine. He is a reader and Director of the Wales Cancer Trials Unit and Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the NCRI anorectal subgroup and is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD.
He chairs the biomarker development group for FOCUS4 is Chief investigator for FOCUS4 D and leads on the radiotherapy quality assurance for the UK ARISTOTLE, COPERNICUS and TREC trials. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Cancer Care link with Sierra Leone.

Professor Mark Saunders, MBBS, MRCP, FRCR, PhD, received his medical degree from Charing Cross Hospital, London, UK, in 1986 and followed this with further training at teaching hospitals in London. He spent 5 years working in general medicine before specialising in oncology, first at the Churchill Hospital in Oxford and later at The Christie in Manchester. During his time as an Imperial Cancer Research Fund Fellow at the Churchill Hospital, Dr Saunders gained a Medical Research Council (MRC) grant to fund work that led to his PhD, entitled “The application of gene therapy to selectively enhance tumour cell kill by bioreductive drugs”, which he completed in 1999. He was the recipient of the Karol Sicher Research Fellowship, awarded by the UK Royal College of Radiologists, which allowed him to spend 3 months working with Professor Ralph Weichselbaum at the University of Chicago. He was made a consultant at The Christie in 1999. His main area of interest is running all phases of chemotherapy and radiotherapy clinical trials evaluating novel agents with associated response / toxicity biomarkers and radiology (colorectal cancer, anal cancer, and pseudomyxoma). He has written a series of protocols for clinical trials that have been funded, completed and published. He also chairs or is a member of a number of Trial Management Groups (TMGs) and Data Monitoring Committees (DMCs). Dr Saunders has been on a member of number of NCRN and CRUK committees and previously chaired the Northern Cancer Drug Fund (CDF) committee. He is the joint-Chair of the medical advisory board of Bowel Cancer UK, a charity dedicated to raising awareness of bowel cancer, improving the quality of life of those affected and, ultimately, reducing deaths from bowel cancer.